GLP-1 weight loss treatment in India

What does GLP-1 mean?

GLP-1 stands for glucagon-like peptide-1, a naturally occurring hormone involved in appetite, digestion and blood-glucose regulation. Medicines acting on the GLP-1 pathway can increase feelings of fullness, reduce appetite and alter gastric emptying. Some were developed for type 2 diabetes; particular products have also been studied for chronic weight management.

GLP-1 describes a class or mechanism, not a brand. Semaglutide is one GLP-1 receptor agonist. Ozempic is a brand containing semaglutide. Brand, formulation, strength and approved indication matter.

What do clinical studies show?

Clinical trials of semaglutide 2.4 mg for chronic weight management have reported substantial average weight reduction when combined with lifestyle intervention. The STEP 1 trial published in the New England Journal of Medicine is a frequently cited example. Trial averages are not predictions for an individual; outcomes vary with tolerance, adherence, nutrition, activity, other medicines and underlying health.

Who may be considered?

Weight-management medicines are considered in the context of BMI, weight-related conditions, previous weight-management efforts and overall clinical risk. Regulatory indications differ by product. CDSCO committee material concerning chronic weight management has referenced adults with BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbid condition.

A medical assessment may cover diabetes, blood pressure, cholesterol, sleep apnoea, cardiovascular history, gastrointestinal symptoms, kidney health, pregnancy plans, mental health, family history and other medicines. Vaya therefore describes eligibility as a doctor-led clinical process rather than an automated website quiz.

How does a doctor-led pathway work?

The process begins with a clinical conversation. A doctor considers whether medical weight management is appropriate and discusses options, expected benefits, limitations and risks. If treatment is prescribed, follow-up can include dose review, tolerability, progress and lifestyle support. Vaya membership starts from ₹699 per month; medication is separate and its cost depends on treatment, dose and dispensing pharmacy.

Why does dose management matter?

Many GLP-1 medicines use a staged dosing schedule. The aim is not simply to reach a higher dose quickly. Follow-up allows tolerability, side effects and response to be reviewed. Patients should follow the instructions supplied with their medicine and seek clinical advice about dose changes, missed doses or restarting treatment.

Side effects and safety

Gastrointestinal effects such as nausea, vomiting, diarrhoea, constipation and abdominal discomfort are commonly reported. Warnings differ by product. Severe or persistent symptoms require medical attention. Patients should disclose all medicines and supplements and read the product information supplied with the medicine.

Questions worth asking

• Which medicine and indication are being considered, and why?
• What would count as a meaningful response?
• How will dose and tolerability be reviewed?
• Which symptoms require prompt medical attention?
• Could treatment interact with existing medicines?
• What happens after a missed dose or interruption?
• How should nutrition, hydration and activity change?
• What is the expected total cost, including medicine and clinical support?

Frequently asked questions

References

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989–1002.
2. Rubino D et al. Continued Weekly Subcutaneous Semaglutide and Weight Loss Maintenance. JAMA. 2021.
3. Central Drugs Standard Control Organisation, Subject Expert Committee recommendations, Endocrinology & Metabolism, 8 April 2026.

Related guides